NASDAQ: VIR
Vir Biotechnology Inc Stock

$10.05+0.35 (+3.61%)
Updated Feb 5, 2025
VIR Price
$10.05
Fair Value Price
N/A
Market Cap
$1.38B
52 Week Low
$6.56
52 Week High
$14.45
P/E
-2.56x
P/B
1.12x
P/S
13.02x
PEG
N/A
Dividend Yield
N/A
Revenue
$78.62M
Earnings
-$533.34M
Gross Margin
98.8%
Operating Margin
-685.83%
Profit Margin
-678.4%
Debt to Equity
0.21
Operating Cash Flow
-$467M
Beta
0.62
Next Earnings
Feb 20, 2025
Ex-Dividend
N/A
Next Dividend
N/A

VIR Overview

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine VIR's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More

Zen Rating Component Grades

C
Value
C
Growth
C
Momentum
D
Sentiment
F
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
VIR
Ranked
#327 of 558

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important VIR news, forecast changes, insider trades & much more!

VIR News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VIR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VIR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VIR is good value based on its book value relative to its share price (1.12x), compared to the US Biotechnology industry average (5.04x)
P/B vs Industry Valuation
VIR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VIR due diligence checks available for Premium users.

Valuation

VIR price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-2.56x
Industry
-153.98x
Market
31.5x

VIR price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.12x
Industry
5.04x
VIR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VIR's financial health

Profit margin

Revenue
$2.4M
Net Income
-$213.7M
Profit Margin
-8,979.7%
VIR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VIR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.5B
Liabilities
$257.6M
Debt to equity
0.21
VIR's short-term assets ($1.05B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VIR's short-term assets ($1.05B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VIR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VIR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$171.5M
Investing
$118.6M
Financing
$31.0k
VIR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VIR vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
VIRD$1.38B+3.66%-2.56x1.12x
NVAXC$1.38B+1.96%-3.93x-2.62x
FTREC$1.40B-1.52%-4.58x0.92x
KNSAC$1.42B+4.75%-151.00x3.24x
ARVNC$1.35B+8.53%-4.09x2.30x

Vir Biotechnology Stock FAQ

What is Vir Biotechnology's quote symbol?

(NASDAQ: VIR) Vir Biotechnology trades on the NASDAQ under the ticker symbol VIR. Vir Biotechnology stock quotes can also be displayed as NASDAQ: VIR.

If you're new to stock investing, here's how to buy Vir Biotechnology stock.

What is the 52 week high and low for Vir Biotechnology (NASDAQ: VIR)?

(NASDAQ: VIR) Vir Biotechnology's 52-week high was $14.45, and its 52-week low was $6.56. It is currently -30.45% from its 52-week high and 53.2% from its 52-week low.

How much is Vir Biotechnology stock worth today?

(NASDAQ: VIR) Vir Biotechnology currently has 137,720,120 outstanding shares. With Vir Biotechnology stock trading at $10.05 per share, the total value of Vir Biotechnology stock (market capitalization) is $1.38B.

Vir Biotechnology stock was originally listed at a price of $14.02 in Oct 11, 2019. If you had invested in Vir Biotechnology stock at $14.02, your return over the last 5 years would have been -28.32%, for an annualized return of -6.44% (not including any dividends or dividend reinvestments).

How much is Vir Biotechnology's stock price per share?

(NASDAQ: VIR) Vir Biotechnology stock price per share is $10.05 today (as of Feb 5, 2025).

What is Vir Biotechnology's Market Cap?

(NASDAQ: VIR) Vir Biotechnology's market cap is $1.38B, as of Feb 7, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Vir Biotechnology's market cap is calculated by multiplying VIR's current stock price of $10.05 by VIR's total outstanding shares of 137,720,120.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.